{"id":"mesencure","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Immune response"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesenchymal stem cells (MSCs) exert therapeutic effects by secreting bioactive factors including cytokines, growth factors, and extracellular vesicles that modulate immune responses and promote tissue repair. These cells can differentiate into multiple cell types and migrate to damaged tissues, where they reduce inflammatory responses and stimulate endogenous regenerative mechanisms. The therapy leverages the immunomodulatory and regenerative properties of MSCs to address degenerative and inflammatory conditions.","oneSentence":"MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:52.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication under investigation in Phase 3 (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT04716998","phase":"PHASE1, PHASE2","title":"Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19","status":"COMPLETED","sponsor":"BonusBio Group Ltd","startDate":"2021-01-14","conditions":"Covid19","enrollment":50},{"nctId":"NCT05497401","phase":"PHASE3","title":"A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS","status":"NOT_YET_RECRUITING","sponsor":"BonusBio Group Ltd","startDate":"2026-04","conditions":"ARDS","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MesenCure","genericName":"MesenCure","companyName":"BonusBio Group Ltd","companyId":"bonusbio-group-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"MesenCure is a mesenchymal stem cell-based therapy designed to promote tissue regeneration and reduce inflammation through paracrine signaling. Used for Indication under investigation in Phase 3 (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}